initial disturbance of SM22α has an influence on AAA formation remains unresolved.
Earlier research has revealed significantly downregulated aortic SM22α expression in AAA individuals and animal AAA models. [8] [9] [10] Combined with the significance of SM22α in maintaining smooth muscle cell (SMC) structure, we postulate that SM22α inhibits AAA formation by preventing SMC phenotypic switching. To verify this postulation, we examined the aortic expression of SM22α in 2 well-established AAA models, as well as in human AAA tissues. Then, we examined the direct effect of aortic SM22α dysregulation-mediated SMC phenotypic switching on AAA formation. We also investigated the signaling responsible for SM22α disruption in AAA formation and how it regulates AAA formation.
Materials and Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Human Aortic Tissue Samples
Human AAA samples were collected from patients undergoing open surgical repair according to protocols approved by Research Ethics Committees of Zhongshan People's Hospital, Sun Yat-sen Hospital, and Guangzhou General Hospital of Guangzhou Military Region. Adjacent nonaneurysmal aortic segments were trimmed from the same patients and used as controls. All aortic tissue samples were used in Western blotting and immunohistochemistry as described previously 11, 12 and in bisulfite sequencing polymerase chain reaction (PCR). All procedures comply with the principles of the Declaration of Helsinki (patient clinical information is available in the onlineonly Data Supplement).
Experimental Animals
Protocols followed the guidelines approved by the Institutional Animal Care and Use Committee at the Southern Medical University. All the animal care and experimental protocols were in accordance with the National Institutes of Health guidelines for the care and use of laboratory animals. Considering the low incidence of experimental AAA in female animals, 13 male mice were used in this study. Male C57BL/6J mice with normal lipid metabolism and male ApoE −/− (apolipoprotein E-deficient) mice on a C57BL/6J background were supplied by the Laboratory Animal Center of Southern Medical University. All mice in the study were fed normal mouse chow. The mice were kept in pathogen-free conditions with a normal chow diet and water under a temperature of 22°C and 60% to 65% humidity with a 12-hour dark/light cycle (lights on at 08:00 am).
Ang II-Induced AAA Model
Ten-to 12-week-old male wild-type mice and 12-to 16-week-old male ApoE −/− mice were used in these studies. An osmotic minipump (Alzet, Model 2004; DURECT Corporation, Cupertino, CA) was subcutaneously implanted in the dorsum of the neck via a small incision; Ang II (A9525; Sigma, St. Louis, MO) or normal saline was infused via the minipump at a well-established rate 1 of 1 μg/kg per minute for 28 days.
14 A half dose of Ang II infusion (0.5 µg/kg per minute) was also used in this study.
CaCl 2 -Induced AAA Model
Before undergoing laparotomy, male C57BL/6J mice were anesthetized by intraperitoneally injected pentobarbital (40 mg/kg −1 ). The abdominal aortic passage below the renal arteries and above the bifurcation of the iliac arteries was isolated from the surrounding retroperitoneal structures. The diameter of this aortic passage was assayed with video microscopy in triplicate. Then, a cotton gauze containing 0.5 mol/L −1 CaCl 2 was spread onto the external surface of the aortic passage for 15 minutes. NaCl (0.9%) was used for a sham operation in control mice. Then, the aorta was rinsed with 0.9% sterile saline, and the incision was sutured. 15 Mice were euthanized at 3 or 6 weeks after CaCl 2 stimulation, and their aortas were harvested for further analysis.
Intervention With N-Acetylcysteine or SN50
As indicated in previous studies, the NF-κB (nuclear factor-κB) blocker SN50 and reactive oxygen species (ROS) antagonist N-acetylcysteine (NAC) were administered to a subset of aortic aneurysm (AA) mice to perform loss-of-function studies. The detailed administration information is listed as follows.
Effect of the NF-κB Antagonist on AA Mice
Ten-week-old male C57BL/6J mice were injected via tail veil with adeno-associated virus (AAV) carrying small-interfering RNA (siRNA) or negative control. At 29 days after infection, mice were randomly assigned to a single intraperitoneal injection of NAC (150 mg/kg per day; n=60) 16 or 1 equivalent infusion of saline (n=60). On the next day, minipump containing Ang II was implanted for 28 days (n=60) or CaCl 2 gauze was administrated (n=60) as mentioned above.
Effect of the ROS Antagonist on AA Mice
Ten-week-old male C57BL/6J mice received a single injection of either SN50 (10 μg/kg per day; n=60) 17 or isometric dimethyl sulfoxide (n=60), followed by the same steps mentioned in Effect of the NF-κB Antagonist on AA Mice.
Aneurysm Quantification
Mice were euthanized and cut open ventrally to confirm the existence of an AA. PBS (10 mL) was injected into the left cardiac ventricle and exited through a cut in the right atrium. Then, the aorta was exposed under a dissecting microscope. The periadventitial tissue was scraped, and the aorta was photographed. The suprarenal aorta was identified as the passage below the last pair of intercostal arteries and above the right renal branch.
The maximum outer width of the abdominal aorta or descending part of the thoracic aorta was measured using Image-Pro Plus software to quantify the AAA size (Media Cybernetics). For quantifying aneurysm incidence, the established human aneurysm definition was adopted, namely, a >50% increase in the outer diameter of the aortas compared with that of aortas from saline-infused mice. Necropsies were performed if mice died during the experimental treatment before being killed. Aortic rupture was defined as the existence of blood clots in the thoracic cavity (thoracic aortic rupture) or in the retroperitoneal cavity (abdominal aortic rupture). Animals that died of aortic rupture were used for the calculation of mortality and rupture rate only and were excluded from tissue degradation analysis. The aneurysm classification (type I-IV) was based on the dilation severity adopted in previous studies, with the following slight amendment 18 : type I, a dilated lumen in the suprarenal aorta, with no or little thrombus formation; type II, a dilated lumen in a prominent bulbous form in the suprarenal aorta, containing a thrombus; type III, dilated lumen with pronounced aneurysms and blood clots from the thoracic aorta through the abdominal aorta; and type IV, subject to ruptured aneurysms.
The intimal and outer width of both the descending thoracic aorta and abdominal aorta was measured as described previously. 4 An evaluation of the AAs was performed by an independent investigator blinded to the experimental treatments. On confirmation of the diameter, area, and aortic classification, a second investigator was invited to match the aneurysm scores to the various treatments of the mice.
Ultrasonography for Aortic Aneurysm
Four weeks after Ang II infusion, surviving mice were anesthetized intraperitoneally with pentobarbital (40 mg/kg −1 ) and underwent 2-dimensional color-coded ultrasound imaging using a Sequoia ultrasound system with a linear-array ultrasound transducer (15 L8-S; mechanical index, 0.17; frequency, 14 MHz; Siemens Medical Systems).
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Histological Analyses
Mice were euthanized, and whole aortas were perfused with saline and fixed with 4% paraformaldehyde at physiological pressure for 5 minutes. The aortas were isolated from the ascending aorta to the entrance of both iliac arteries for macroscopic analysis. Then, the aortas were segmented to obtain suprarenal abdominal aortas (for Ang II-induced AA models) or infrarenal abdominal aortas (for CaCl 2 -induced AA models). Aortic samples were harvested, fixed for 24 hours, and embedded in paraffin. Histology was examined in crosssections (5 μm each) that were taken from these aortic samples at intervals of ≈500 μm. At least 10 sections were analyzed per mouse. Paraffin sections were stained with elastin van Gieson staining or used for immunostaining.
Cell Culture and Treatment
Aortic VSMCs (MOVAS-1) were purchased from Guangzhou Geneseed Biotech, Ltd. VSMCs were kept in DMEM with fetal bovine serum (10%), 100 U/mL penicillin, and 100 µg/mL streptomycin. VSMCs were maintained at 37°C in a humidified atmosphere containing 5% CO 2 . Cells were used between passages 3 and 6 and were grown to 70% to 80% confluence before being treated with different agents in all experiments. Then, homocysteine solution (25 μg/ mL; Sigma) was added to the VSMC medium, and cells were incubated at room temperature for 24 hours, 20 followed by application of the following treatments: (1) the DNA methyltransferase inhibitor 5′-aza-deoxycytidine (5 µmol/L) was incubated at room temperature for 48 hours 21 and (2) PBS was applied as the negative control and incubated at room temperature for 48 hours. At the end of the incubation, VSMCs were obtained and used for SM22α RNA or protein expression assays.
RNA Interference and Cell Transfection
Specific siRNAs against SM22α and nonspecific controls were synthesized by GenePharma (Shanghai, China; sequences of siRNAs are available in the online-only Data Supplement). SM22α siRNA was synthesized by Vigene Bioscience (Jinan, Shandong, China). The overexpression plasmid, pEnter-SM22α (GenBank accession No. NM_011526.5), was synthesized by Vigene Bioscience (Jinan, Shandong, China). VSMCs were seeded into 6-well plates and cultured for 24 hours. Then, 50 nmol/L siRNA or 4 μg pEnter-SM22α was randomly added to 250 µL Opti-Minimum Essential Medium (Gibco BRL, Paisley, United Kingdom) before the addition of 5 μL lipofectamine 3000 (L3000015; Invitrogen). Then, the mixed solution was incubated at room temperature for 0.5 hours and added to the cells. After 6 hours of incubation, the medium was replaced at 37°C with the same volume of DMEM. After 48 hours, the cells were subjected to immunofluorescence analysis, RNA isolation, or protein isolation.
The SM22α AAV was constructed and packaged by Vigene Biosciences (Jinan, China). Specific siRNAs against SM22α and nonspecific controls were separately constructed in one vector, and AAV serotype 9 harboring these sequences was generated by Vigene Biosciences (Jinan, China). Mice were injected one of the above virus (5×10 9 pfu/kg). After 24 hours, the mice were randomly grouped and treated with Ang II or CaCl 2 as indicated previously.
Immunohistochemistry Analysis
Mouse samples were deparaffinized, and endogenous peroxidase activity was blocked by 3% (vol/vol) hydrogen peroxide, followed by preincubation with 10% bovine serum to block nonspecific binding sites. 22 Then, slides were incubated at 4°C overnight with primary antibodies (in 1% BSA) and a biotinylated secondary antibody (in 1% BSA) and subsequently incubated with a horseradish peroxidaselabeled streptavidin solution. Then, the slides were stained with diaminobenzidine and counterstained with hematoxylin. The primary antibodies used were mouse SM22α, α-SMA (α-smooth muscle actin), MYH11 (myosin heavy chain 11), MMP (matrix metalloproteinase) 2, MMP9, MAC2 (galectin 3), and rabbit IgG for both Ang II-and CaCl 2 -induced AA mouse models. Negative control experiments were performed to confirm specificity of antibody binding in Ang II-treated male ApoE −/− mice; information about antibodies is available in the online-only Data Supplement).
Immunofluorescent Staining
Immunofluorescent staining was performed with 5 μm frozen sections from the suprarenal abdominal aortas. Frozen sections were fixed with acetone, followed by blockade with 1% bovine serum in PBS at room temperature for 1 hour and then incubated at 4°C overnight with diluted (AAPR67-100; PanEra) primary antibodies anti-SM22α and anti-H-caldesmon. Secondary antibodies were replaced with antibodies labeled with Alexa Fluor dye with a maximum excitation at 488 nm (green), and for red with Alexa Fluor 568, which were incubated at 37°C for 45 minutes in the dark. Sections were stained simultaneously, using identical reagents and incubation times. The slides were then rinsed with PBS, and images were captured by fluorescence inverted microscope (IX83; Olympus; information about antibodies is available in the online-only Data Supplement).
Elastin Staining and Degradation
The definition and graduation of elastin degradation were described elsewhere. 23 Briefly, suprarenal aortic samples from the different groups of mice were embedded in paraffin, cut, and then measured with Victoria-blue van Gieson staining by applying a commercial kit (GenMed, Shanghai). We used ×40 magnification to evaluate elastin degradation. A previously established standard for the elastin degradation score was adopted as follows 23 : score 1, no elastin degradation, e13
well-organized elastin lamina; score 2, mild elastin degradation with some interruptions or breaks in the lamina; score 3, moderate elastin degradation with multiple interruptions or breaks in the lamina; and score 4, severe elastin fragmentation or loss or aortic rupture.
Western Blots
Aortic protein expression levels were measured using Western blots as described previously. 24 The separated mouse aortic tissues containing identical amounts of protein were denatured and resolved by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis using a 10% running gel. Then, proteins were dissociated using 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and probed with primary antibodies for SM22α, MCP-1 (monocyte chemotactic protein-1), MMP2, MMP9, NF-κB P65, β-actin, lamin A/C, RelB, c-Rel, p50, p52, IKKβ (inhibitor of NF-κB kinase subunit-β), p-IKKβ, IκBα (nuclear factor of κ light polypeptide gene enhancer in B-cells inhibitor-α), p-IκBα, or caspase-3 at 4°C overnight. All primary antibody reagents were diluted by AAPR67-100 (PanEra). Next, the membranes were washed and incubated with a horseradish peroxidase-conjugated anti-rabbit secondary antibody at a 1:5000 dilution (DAKO) for 2 hours. β-actin was used as a loading control. Bands were detected using enhanced chemiluminescence (Advance, No. RPN2235; GE Healthcare Life Sciences). The protein intensity was determined, quantified, and normalized to that of β-actin by using a ChemiDoc imaging system (Bio-Rad Laboratories), and ImageJ Analysis software (National Institutes of Health, Bethesda, MD) was used for protein expression analysis. All experiments were replicated 3×; information about antibodies is available in the online-only Data Supplement).
MMP2 and MMP9 Quantification
Quantification of MMP2 and MMP9 was determined by using IPP software, based on the integral optical density (IOD) value, the sum of the chroma, and acreage of positive color (claybank). The mean IOD was calculated as the IOD value divided by the acreage of the samples. Each specimen had 3 lower power sections and 9 higher power sections. The mean IOD was the mean value of the IOD value in the 9 higher power sections.
Quantitative Real-Time PCR
Total RNA of ex vivo VSMCs or of aortic tissues from different mouse groups was extracted by homogenization using TRIzol reagent (Invitrogen) according to the manufacturer's protocol and then converted to cDNA following standard methods. cDNA was synthesized by reverse transcriptase (Takara Biotechnology, Dalian, China) using the primer sequences for the examined molecules. Real-time PCR was performed with a SYBR Green RT-PCR Kit (Takara Biotechnology) using Light Cycler 480 II equipment (Roche Diagnostics, Basel, Switzerland). The relative expression of mRNA was determined using the 2-ΔΔCt method by normalizing the expression against that of β-actin. Primers were synthesized by Saicheng Biotech (Guangzhou, China; primers for quantitative real-time PCR are available in the online-only Data Supplement).
Immunoprecipitation
Coimmunoprecipitation was conducted using an antibody against phosphorylated-Ser, and the precipitation was performed via coincubation with an antibody against p47 phox . Briefly, total protein extracts from aortic wall were pretreated 50 mmol/L Tris-HCl (pH 8), 150 mmol/L NaCl, 1% Nonidet P-40, and protease (1 mmol/L phenylmethylsulfonyl fluoride, 40 µg/mL −1 aprotinin, and 40 µg/mL −1 leupeptin) and phosphatase (1 mmol/L sodium orthovanadate and 1 mmol/L NaF) inhibitors, followed by incubation with 5 µg (per 200 µg protein) of a rabbit monoclonal antibody against phosphorylatedser primer antibody reagents were diluted by primary antibody dilution buffer (AAPR67-100; PanEra). Bound proteins were precipitated with anti-rabbit IgG beads (cat 8800; eBioscience, San Diego, CA) for 1 hour with rocking at 4°C, followed by incubation with protein A-agarose overnight at 4°C; then, the proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and Western blots were performed as described above (information about antibodies is available in the online-only Data Supplement).
ROS Analysis
For the detection of vascular ROS activity, suprarenal abdominal aortas were harvested and embedded vertically in tissue optimal cutting temperature freezing medium (Tissue-Tek; Miles, Elkhart, IL), snap-frozen, cross-sectioned (7 mm), and then incubated with dihydroethidium (5 mol/L −1
; Sigma) for 30 minutes at 37°C. Sections were examined by using a fluorescence inverted microscope (Leica Imaging Systems, Cambridge, United Kingdom) to reveal the existence of ROS as red fluorescence (585 nm).
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Bisulfite Sequencing PCR
The methylation status of the promoter regions of SM22α in human and mouse AA samples was detected by bisulfite sequencing PCR. Bisulfite sequencing PCR-specific primer pairs for the SM22α gene were generated with MethPrimer (http://www.urogene.org/ methprimer/; bisulfite sequencing PCR-specific primer is available in the online-only Data Supplement).The human and mouse SM22α gene CpG island regions contained 15 and 10 CpG dinucleotides, respectively. The human SM22α gene contained promoter regions spanning from −290 to −32 bp relative to the transcription start site of human SM22α transcript variant 1. The mouse SM22α gene contained promoter regions spanning from −222 to −3 bp relative to the transcription start site of mouse SM22α transcript variant 1. DNA was treated with bisulfite and amplified with PCR under the following conditions (as in previous studies): denaturation at 95°C for 5 min; 30 cycles of 95°C for 30 s, 55°C for 30 s, and 72°C for 30 s, with extension for 10 minutes at 72°C. The amplified products were then gel purified and cloned into a pMD 19-T vector (Invitrogen). Ten clones from each sample were randomly selected for plasmid DNA extraction with a Qiagen Plasmid Mini Kit (Qiagen) and DNA sequencing.
Statistical Analysis
Values are presented as the mean±SD. The data were analyzed using SPSS, version 20.0 (SPSS, Inc, Chicago, IL). Normal distribution test was performed for all continuous variables. After confirmation of variance equality among different groups, statistical differences between 2 independent groups were analyzed using unpaired Student t test, whereas statistical difference among ≥3 groups was analyzed using 1-or 2-way ANOVA followed by post hoc test of Dunnett. If a normal distribution could not be determined, nonparametric tests were applied Mann-Whitney U test for 2 independent groups. Fisher exact test was applied for the analysis of aneurysm incidence. The correlation between gene promoter methylation status and the expression of the VSMC SM22α gene was explored by Spearman correlation. P <0.05 was considered statistically significant.
Results
SM22α Is Downregulated in Human and Mouse AAA Tissues
Human intimal and medial AAA sections and the corresponding adjacent normal aortic tissues were obtained from patients undergoing AAA resection surgery. Western blotting results showed that the protein expression of SM22α was remarkably lower in AAA tissues than in corresponding adjacent normal aortic tissues (P<0.01) and was accompanied by significantly elevated MMP2 (P<0.05) and MMP9 (P<0.01), which are 2 extracellular matrix proteolytic enzymes that are crucially implicated in AAA formation ( Figure 1A ). Immunohistochemistry staining confirmed that the levels of We further investigated the expression of SM22α in the AAA mouse model. As shown by 2-dimensional ultrasonography and color-coded Doppler imaging, a dilated abdominal aorta was seen at 14 days after Ang II infusion in ApoE −/− mice ( Figure 1D ). Macroscopy showed formed aneurysm at 28 days after Ang II infusion in ApoE −/− mice ( Figure 1E ) or at 3 weeks after CaCl 2 treatment in C57BL/6J mice ( Figure 1F concordant between human AAA and mouse AAA. These findings were consistent with the findings during the process of SMC phenotypic switching to some extent.
Hypermethylation of the SM22α DNA Promoter Occurs in Human and Mouse AAA Tissues
We explored whether decreased SM22α expression during AAA formation is relevant to the enhanced methylation level of the SM22α gene promoter. A bisulfite sequencing PCR technique was adopted to detect methylated CpG sites (CpG islands) in both human and mouse SM22α promoters (Figure 2A and 2B) . Five samples from human AAAs and adjacent normal specimens ( Figure 2C ) and 5 samples from Ang II-induced ApoE −/− mouse AAAs and adjacent normal aortic tissues ( Figure 2D) were assessed. Each mouse sample was a mixture of aortic tissues from 3 individual specimens. Thus, an adequate amount of aortic tissue was obtained for measurements. The percentage of methylated CpG sites in the SM22α promoter was substantially higher in human AAA samples and in mouse Ang II-induced AAA samples than in their respective control samples (Figure 2B and 2D ; P<0.01). Similar results were found 28 days later in CaCl 2 -induced AAA mice compared with those in sham-control mice ( Figure 2E ; P<0.05). Because SMC phenotypic switching already occurs in the early phase of AAA pathogenesis, we explored whether the SM22α gene promoter underwent significant DNA methylation alterations in the early days. Accordingly, SM22α promoter methylation levels in aortic VSMCs were detected on the first, fourth, and seventh day after Ang II treatment. Compared with the control group, the Ang II group showed a mild but nonsignificant increase in methylated nucleotides in the mouse aortic SM22α promoter on the first day ( Figure 2F ). This upregulation became significant 4 (P<0.05) and 7 (P<0.05) days after Ang II administration ( Figure 2F and 2H) . We further detected the aortic SM22α production rate during this period and found significant reductions in SM22α mRNA levels ( Figure IIB in the online-only Data Supplement) and protein expression levels ( Figure IIC and IID in the online-only Data Supplement) on the fourth (P<0.01) and seventh day (P<0.01) compared with those on the first day. Importantly, we accordingly identified a negative association between the SM22α expression level and SM22α promoter methylation status ( Figure IIA in the onlineonly Data Supplement). Furthermore, an appropriate dose of 5′-aza-deoxycytidine-a DNA demethylating agent-was administered to ex vivo VSMCs for 24 hours. Consequently, the SM22α gene exhibited substantially increased SM22α transcription (P<0.01) and protein expression (P<0.01; Figure  IIE through IIG in the online-only Data Supplement) in VSMCs. We further evaluated dnmt levels in human AAA and Ang II-or CaCl 2 -induced mouse AAA and found that dnmt1 and dnmt3b but not dnmt3a were substantially upregulated in human and mouse AAA specimens ( Figure IIIA 
Targeting SM22α Influences the Development of AAA
To further identify a potential causative link between disturbed SM22α expression and AAA development, we selected an AAV carrying SM22α siRNA or SM22α overexpression plasmid to perform gain-or loss-of-function studies in Ang II-perfused ApoE −/− mice AAV-GFP (green fluorescent protein), AAV-SM22α, Scr-RNA, and sh-SM22α groups. First, 4 siRNA sequences and pcDNA3.1-SM22α were separately and successfully integrated into transfected cultured VSMCs. The detection of SM22α mRNA levels in ex vivo VSMCs reflected that siRNA 1 and pcDNA3.1 were the most potent in inhibiting and promoting SM22α expression, respectively ( Figure IVA and IVB in the online-only Data Supplement). Serial aortic SM22α protein expression levels were assessed on the 15th, 30th, 40th, 50th, and 60th days ( Figure IVC in the online-only Data Supplement). Beginning at the 30th day, as anticipated, both knockdown and overexpression interventions yielded significant and continuous inhibition and promotion of SM22α expression, respectively, compared with that yielded by no intervention ( Figure 3A and 3B) . Moreover, compared with the saline control group, both the sh-SM22α group and AAV-SM22α group had a significantly enhanced aortic GFP signal, indicating a high efficiency of viral transfection ( Figure VA and VB in the online-only Data Supplement). Then, on the 30th day, a proportion of the ApoE −/− mice was randomly selected to start receiving an Ang II infusion for 28 days ( Figure IVD in the online-only Data Supplement). Considering that SM22α has been reported to promote transition of adventitial fibroblasts to a myofibroblast phenotype, 25 we further evaluated whether adventitial fibroblasts can affect the role of SM22α on AAA. Results of coimmunofluorescence staining with SM22α and H-caldesmon revealed that the H-caldesmon-stained areas were overlapped with the SM22α-stained areas, indicating that SMCs but not aortic adventitial fibroblasts were affected by AAV intervention ( Figure AA classification of I, II, III, and IV, respectively, in the Scr-RNA group; P<0.05; Figure 3C through 3E). AA formation was nearly absent in AAV-SM22α mice compared with that in AAV-GFP mice, which displayed a substantial bulge in the abdominal aorta (10 of 30 mice, 33.3%; 10 AAAs; 3, 3, 0, and 5 with an AA classification of I, II, III, and IV, respectively, in the AAV-SM22α group; 21 of 31 mice, 67.7%; 21 AAAs; 4, 6, 1, and 10 with an AA classification of I, II, III, and IV, respectively, in the AAV-GFP group; P<0.05; Figure 3C through 3E). In addition, the maximal diameters of the descending thoracic aorta ( Figure VIA in the online-only Data Supplement) and abdominal aorta ( Figure 3G ) were substantially higher in the sh-SM22α group than in the Scr-RNA group and were substantially lower in the SM22α overexpression group than in the AAV-GFP group. Correspondingly, the Ang II-induced elastin degradation scores for both the abdominal (Figure 4A and 4B) and descending thoracic ( Figure VIB in the online-only Data Supplement) aortas were significantly higher in the sh-SM22α group than in the Scr-RNA group (P<0.05), with a milder change in the thoracic aorta than in the abdominal aorta. In contrast, elastin degradation in both aortic regions was effectively prevented in AAV-SM22α mice compared with that in AAV-GFP mice. Western blotting results showed that the aortic cleaved caspase-3 expression did not significantly differ between AAV-SM22α and AAV-GFP groups ( Figure in normolipidemic circumstances, we administered an Ang II infusion to wild-type C57BL/6J mice for 28 days. Consistent with the findings in ApoE −/− mice, after 14 days of Ang II infusion, bulges were detected by 2-dimensional ultrasonography and color-coded Doppler imaging in abdominal aorta from the C57BL/6J mice in sh-SM22α group ( Figure 5B) . The AAA morbidity ( Figure 5A and 5B), maximal aortic diameter ( Figure 5C ), AAA morbidity (18 of 30 mice; 18 AAAs; 5, 6, 5, and 2 with an AA classification I, II, III, and IV, respectively, in the sh-SM22α group; 5 of 30 mice; 5 AAAs; 1, 1, 0, and 0 with an AA classification of I, II, III, and IV, respectively, in the Scr-RNA group; P<0.05; Figure 5D and 5E), SM22α protein expression (P<0.05; Figure 5F and 5G), and elastin degradation status (P<0.05; Figure 5H ) showed similar deteriorated tendencies. Based on these findings, SM22α deficiency was potent enough to instigate AA onset under Ang II therapy in the absence of hyperlipidemia.
Disruption of SM22α Promotes AAA Formation in CaCl 2 -Infused Mice
To explore whether the effects of vascular SM22α disruption on AAA formation are partially independent of Ang II pathway signaling, we examined the role of SM22α deficiency in the CaCl 2 -induced AAA model. Three weeks after CaCl 2 application in the adventitia of the mouse infrarenal aorta, the maximal aortic diameter ( Figure IXA 
SM22α Inhibits ROS Bioactivity and NF-κB Activation
Accumulating lines of evidence have proven that ROS can activate NF-κB, subsequently triggering a cascade of inflammatory responses, including enhanced MMP and MCP-1 expression in various diseases. Thus, we sought to determine whether SM22α disruption promotes proinflammatory molecule expression via the ROS/NF-κB pathway. At 28 days after Ang II infusion, the cytoplasmic levels of p65 and p50 of the NF-κB family were significantly decreased, whereas nuclear p65 and p50 were significantly elevated in the sh-SM22α group than in the Scr-RNA group, indicating a transfer of aortic NF-κB from cytoplasm to nucleus to execute functions as a response to aortic SM22α deficiency. In contrast, the activity of p65 and p50 was suppressed in the AAV-SM22α group (Figure 6C and 6D) . Conversely, aortic phosphorylated IκBα (p-IκBα) and IKKβ (p-IKKβ) were reduced on SM22α overexpression and increased on SM22α deficiency ( Figure 6A and 6B) . Aortic ROS level, as indicated by immunofluorescence staining, exhibited the same significant trends in alterations as those observed for NF-κB expression ( Figure 6E and 6F) . Nonetheless, there were no obvious changes in the levels of the remaining members of the NF-κB family, including RelB, c-Rel, and p52, in the nucleus and cytoplasm ( Figure XII in the online-only Data Supplement).
SM22α Inhibits the Phosphorylation of the p47 phox Subunit of Nicotinamide Adenine Dinucleotide Phosphate Oxidase
SM22α disturbance has been demonstrated to facilitate ROS enhancement through promoting p47 phox phosphorylation and abnormal cell structure. 26 Based on these findings, we determined whether SM22α deficiency promotes ROS through upregulated p47
phox phosphorylation. Immunoprecipitation analysis showed that phosphorylated p47 phox was significantly increased as SM22α was deregulated, whereas it was inhibited as SM22α was upregulated ( Figure 7A through 7C) . Moreover, cytoskeletal structure instability, as reflected by the actin cytoskeletal fraction/cytosolic soluble actin ratio, was significantly decreased in the AAV-SM22α group and significantly increased in the sh-SM22α group compared with that in their respective control groups ( Figure 7D) . Accordingly, our results demonstrated a causal relationship between SM22α deficiency and 47 phox phosphorylation and cytoskeletal destruction, which partially explained the enhanced ROS/ NF-κB signaling activation, vascular inflammation, and AAA formation.
Inhibition of NF-κB or ROS Blocks AAA Formation
To determine the obligatory role of the ROS/NF-κB pathway in SM22α deficiency-mediated AAA formation, we performed rescue experiments by separately using NF-κB antagonist SN50 or ROS inhibitor NAC 1 day before 28 days of Ang II infusion in C57BL/6J mice. We observed that compared with PBS administration, either SN50 or NAC administration partially abolished the promoting effect of SM22α deficiency on AAA formation and maximal aortic diameter ( Figure 8A through 8G). As anticipated, aortic ROS production was sufficiently inhibited by NAC treatment in SM22α-deficient mice, which was confirmed by a quantitative analysis of the fluorescence signal intensity ( Figure 8H and 8I) . Western blot analysis revealed that SN50 substantially decreased nuclear p50 and p65, indicating an inhibition of NF-κB ( Figure 8J through 8L). Similar trends were observed at 3 weeks after CaCl 2 treatment in C57BL/6J mice ( Figure XIII in the online-only Data Supplement). Taken together, our results indicated that the ROS/NF-κB pathway is involved in SM22α deficiencypromoted AAA development.
Discussion
In the current study, SM22α overexpression inhibited SMC modulation from a contractile to synthetic phenotype and exerted a protective effect against AAA formation in both Ang II-perfused and CaCl 2 -induced AAA models. In contrast, SM22α knockdown exacerbated this SMC switching and AAA formation. Consistent trends were also found in extended models using half-dose Ang II-infused mice and CaCl 2 -treated mice after 6 weeks. The mechanisms underlying this phenomenon were demonstrated in the findings that DNA hypermethylation-associated SM22α deficiency could activate the aortic ROS/NF-κB pathway and proinflammatory and matrix proteolytic molecules MCP-1 and MMPs. These changes provided a vascular environment susceptible to inflammation and predisposed the aorta to aneurismal formation.
With the increased awareness of disease prevention and advanced technology for the detection and diagnosis of AAA, the incidence of small, insidious AAA (≤5 cm in diameter) has markedly increased. 27 Despite the consensus that the best strategy for AAA management emphasizes early intervention, 28 limited progress has been made in managing patients with small AAA because there are no effective drugs for preventing and 18 Type IV represents ruptured aneurysms. E, Maximal abdominal aortic aneurysm (AAA) diameter in the Ang II-treated C57BL/6J mice. F and G, Western blots of the protein levels (F), representative staining of the SM22α protein (G; scale bars=200 and 50 µm), and the corresponding densitometric analysis in Ang II-treated C57BL/6J mice between 2 groups (n=3). H, Representative staining with elastin and the elastin degradation score in aortas from C57BL/6J mice treated with Ang II (scale bars=200 and 50 µm). The presented photographs were obtained at the location where the most severe elastin degradation occurred. Data are presented as the mean±SD. **P<0.01.
reversing AAA advancement. 29, 30 Vascular pathology mediated by SMC phenotypic switching plays a vital role during AAA formation. 8, 31, 32 In previous studies, SM22α has generally been considered one of the hallmarks of SMC phenotypic switching. 8, 33 However, whether SM22α has interventional value in AAA management remains unexplored. In our study, SM22α protected against AAA initiation through inhibiting the activation of the ROS pathway in 2 well-accepted AAA models, whereas SM22α knockdown intensified AAA formation. Our study confirms a crucial role of SM22α in AAA development other than its role as a biomarker of SMC structure. Our study, combined with others elucidating the role of SM22α in vessels, highlights the significance of SM22α in maintaining vascular integrity and function, [34] [35] [36] [37] thus indicating the great therapeutic potential of targeting SM22α in the treatment of vascular diseases. Moreover, this finding provides a new direction for effective/potential treatments for AAA. Theoretically, detection of and preventative interventions against pathogenic factors during the inchoate stage of a disease are more advantageous for intercepting further pathogenic deterioration and thus protecting against later manifestations and progression when the disease has already formed. SMC apoptosis certainly represents a critical pathophysiological process 9, 38 ; however, it occurs in a relatively late phase during AAA development. In agreement with former studies, we also found that SM22α expression was reduced in the early days in both models. This observation, along with those of earlier works, indicates that SMC phenotypic switching might be an early triggering event in AAA pathogenesis. 9 In addition, this kind of SMC transition was associated with significantly higher DNA hypermethylation in the SM22α promoter region, which was detected as early as the fifth day of Ang II intervention and remained stable until the seventh day. Given that epigenetic alterations in gene promoters (such as DNA hypermethylation) occur even ahead of aberrant gene expression and that DNA hypermethylation is regarded as a stable DNA modification, 40, 41 SM22α promoter hypermethylation might be a potential robust marker for the recognition of early AAA formation or progression risk.
Mechanistically, we found aberrant NF-κB activation, an abnormal inflammatory response, and MMP fluctuation under SM22α dysregulation in both AAA models. Our study reveals the ability of SM22α to influence the above inflammatory molecules and MMPs in AAA models. In agreement with our findings, SM22α deficiency was previously shown to contribute to increased macrophage infiltration in an atherosclerosis model and to promote proinflammatory genes and MMP2/9 expression in mouse carotid intimal injuries. 37, 42, 43 These results might provide theoretical clues on how adventitial inflammatory cell accumulation develops into transmural vascular inflammation. Medial SMC phenotypic switching might even advance with the help of early inflammatory activation from the aortic adventitia because SMCs can undergo phenotypic switching in response to multiple inflammatory cytokines. 44 In turn, this SMC switching might further mediate medial aortic inflammatory cell infiltration and MMP secretion, thus facilitating AAA development. We further explored the upstream molecule essential for NF-κB activation. In our study, SM22α knockdown stimulated actin cytoskeleton disorganization, increasing phosphorylated p47 phox -the centrally functioning subunit of nicotinamide adenine dinucleotide phosphate oxidase-and triggering the cascade of ROS production. 26, 37 We revealed a role for SM22α insufficiency in promoting ROS generation and subsequent NF-κB activation in AAA. Consistently, a number of studies have confirmed the role of this signaling pathway in SM22α-knockdown mice. Using a carotid injury model, Shen et al 37 found that the systemic knockout of SM22α increases the cellular ROS level possibly through disordered actin arrangement, consequently activating NF-κB and its downstream proinflammatory genes. Additionally, another study found that the knockdown of SM22α triggers actin cytoskeleton disorganization in VSMCs, increasing the phosphorylation of p47 phox -a central subunit of nicotinamide adenine dinucleotide phosphate oxidase-and enhancing intracellular ROS levels. 26 Our observations indicate that cytoskeletal remodeling induced by SM22α disruption may activate ROS production and enhance downstream NF-κB in the context of AAA.
Next, we verified whether this ROS/NF-κB pathway is indispensable in associating SM22α knockdown with AAA formation by using the antagonist SN50 or inhibitor NAC. We found that SN50 or NAC partially reversed the SM22α deficiency-exacerbated AAA formation, as well as the related vascular pathophysiological changes, namely, elevated aortic MMP2/9 and proinflammatory molecule levels. Previous studies showed that SM22α loss of function resulted in enhanced expression of proinflammatory genes that are governed by NF-κB in aortic VSMCs. 26, 37 Our results, along with multiple previous studies reporting that SM22α knockdown could activate the ROS/NF-κB pathway, 26 confirm the crucial role of the NF-κB pathway in strengthening the abovementioned proinflammatory factors and MMP2/9 elevation in SM22α deficiency-mediated SMC phenotypic switching in AAA formation. Nonetheless, other mechanisms await investigation. A recent report suggested that SM22α promotes the phosphorylation and activation of SIRT1 (sirtuin 1) by recruiting CKII (casein kinase II) and SIRT1, which augments the anti-inflammatory effect of SIRT1 and is considered effective for suppressing AAA development. 43 Our study along with earlier works thoroughly demonstrates the role of disturbed SM22α in vascular disorder development and indicates that SM22α has great potential for therapeutic intervention.
This study has some limitations. First, the exact mechanisms remain unsolved and require additional research for further illumination. Second, in our experiment, SM22α was systemically affected, not specific to VSMCs. Although SM22α overexpression in adventitial fibroblasts may induce their transition to myofibroblasts that secrete various cytokines and inflammatory molecules, previous studies have suggested that this transition is mainly instigated by vascular ROS activation. 25 Because excessive SM22α in VSMCs was demonstrated to reduce vascular ROS level, 37, 43, 45 this transition might be hindered and even abrogated by the low level of ROS as a result of VSMC SM22α overexpression.
In conclusion, we confirm that SM22α downregulation has a causative role in AAA formation, which is mediated through internally instigated SMC phenotypic switching by activation of the ROS/NF-κB pathway. In addition, DNA hypermethylation is associated with AAA formation by affecting the SM22α expression level. These inchoate changes might be biochemically detectable before the catastrophic disturbance leading to AAA, contributing a novel and promising target for early AAA detection and intervention.
